# Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas

> **NCT01318642** · PHASE2 · TERMINATED · sponsor: **NantBioScience, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Locally Advanced
- Unresectable

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** AMG 479
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01318642
- **Lead sponsor:** NantBioScience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05-31
- **Primary completion:** 2012-11-27
- **Final completion:** 2012-12-03
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** NCT01318642: Planned independent DMC Interim review: ended for futility
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01318642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01318642, "Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01318642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*